Literature DB >> 32805236

Mortality Trends of Idiopathic Pulmonary Fibrosis in the United States From 2004 Through 2017.

Niranjan Jeganathan1, Rory A Smith2, Matheni Sathananthan3.   

Abstract

BACKGROUND: The burden of idiopathic pulmonary fibrosis (IPF)-related mortality in the United States in recent years is not well characterized. RESEARCH QUESTION: What are the trends in IPF-related mortality rates in the United States from 2004 through 2017? STUDY DESIGN AND METHODS: We used the Multiple Cause of Death Database available through the Centers for Disease Control and Prevention website, which contains data from all deceased US residents. IPF-related deaths were identified using International Classification of Diseases, 10th revision, codes. We examined annual trends in age-adjusted mortality rates stratified by age, sex, race, and state of residence. We also evaluated trends in place of death and underlying cause of death.
RESULTS: From 2004 through 2017, the age-adjusted mortality decreased by 4.1% in men (from 75.5 deaths/1,000,000 in 2004 to 72.4 deaths/1,000,000 in 2017) and by 13.4% in women (from 46.3 deaths/1,000,000 in 2004 to 40.1 deaths/1,000,000 in 2017). This overall decrease was driven mainly by a decline in IPF-related mortality in patients younger than 85 years. The decreasing trend also was noted in all races except White men, in whom the rate remained stable. The most common cause of death was pulmonary fibrosis. The percentage of deaths occurring in the inpatient setting and nursing homes decreased, whereas the percentage of deaths occurring at home and hospice increased.
INTERPRETATION: From 2004 through 2017, the IPF age-adjusted mortality rates decreased. This may be explained partly by a decline in smoking in the United States, but further research is needed to evaluate other environmental and genetic contributors.
Copyright © 2020 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cause of death; idiopathic interstitial pneumonia; idiopathic pulmonary fibrosis; mortality rates; mortality trends; pulmonary fibrosis

Year:  2020        PMID: 32805236     DOI: 10.1016/j.chest.2020.08.016

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  8 in total

1.  The association of lung cancer with pulmonary fibrosis.

Authors:  Niranjan Jeganathan; Derrick Cleland; Matheni Sathananthan
Journal:  ERJ Open Res       Date:  2022-01-10

Review 2.  Inflammation, Fibrosis and Cancer: Mechanisms, Therapeutic Options and Challenges.

Authors:  Bocheng Wu; Quaovi H Sodji; Adegboyega K Oyelere
Journal:  Cancers (Basel)       Date:  2022-01-22       Impact factor: 6.639

3.  The prevalence and burden of interstitial lung diseases in the USA.

Authors:  Niranjan Jeganathan; Matheni Sathananthan
Journal:  ERJ Open Res       Date:  2021-02-07

Review 4.  Mortality and survival in idiopathic pulmonary fibrosis: a systematic review and meta-analysis.

Authors:  Qiang Zheng; Ingrid A Cox; Julie A Campbell; Qing Xia; Petr Otahal; Barbara de Graaff; Tamera J Corte; Alan K Y Teoh; E Haydn Walters; Andrew J Palmer
Journal:  ERJ Open Res       Date:  2022-03-14

Review 5.  Contemporary Concise Review 2021: Interstitial lung disease.

Authors:  Cormac McCarthy; Michael P Keane
Journal:  Respirology       Date:  2022-05-05       Impact factor: 6.175

6.  Sepsis-Related Mortality Rates and Trends Based on Site of Infection.

Authors:  Jonathan Prest; Thai Nguyen; Tiffany Rajah; Alayna B Prest; Matheni Sathananthan; Niranjan Jeganathan
Journal:  Crit Care Explor       Date:  2022-10-10

7.  All-cause mortality of patients with idiopathic pulmonary fibrosis: a nationwide population-based cohort study in Korea.

Authors:  Sung Jun Ko; Sun Mi Choi; Kyung-Do Han; Chang-Hoon Lee; Jinwoo Lee
Journal:  Sci Rep       Date:  2021-07-26       Impact factor: 4.379

Review 8.  Idiopathic Pulmonary Comorbidities and Mechanisms.

Authors:  Maricica Pacurari; Amal Mitra; Timothy Turner
Journal:  Int J Inflam       Date:  2021-10-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.